NKGen Biotech, holds a performance score of 22 on a scale of zero to a hundred. The company secures a Beta (Market Risk) of 9.4, which conveys a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, NKGen Biotech, will likely underperform. Use NKGen Biotech Common total risk alpha and the relationship between the potential upside and day typical price , to analyze future returns on NKGen Biotech Common.
Risk-Adjusted Performance
Solid
Weak
Strong
Compared to the overall equity markets, risk-adjusted returns on investments in NKGen Biotech Common are ranked lower than 22 (%) of all global equities and portfolios over the last 90 days. In spite of very uncertain technical and fundamental indicators, NKGen Biotech, displayed solid returns over the last few months and may actually be approaching a breakup point. ...more
Begin Period Cash Flow
117 K
Free Cash Flow
-22 M
NKGen
NKGen Biotech, Relative Risk vs. Return Landscape
If you would invest 0.02 in NKGen Biotech Common on October 5, 2025 and sell it today you would earn a total of 4.98 from holding NKGen Biotech Common or generate 24900.0% return on investment over 90 days. NKGen Biotech Common is currently generating 16.7711% in daily expected returns and assumes 59.8361% risk (volatility on return distribution) over the 90 days horizon. In different words, most equities are less risky than NKGen, and most traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon.
Expected Return
Risk
Given the investment horizon of 90 days NKGen Biotech, is expected to generate 82.05 times more return on investment than the market. However, the company is 82.05 times more volatile than its market benchmark. It trades about 0.28 of its potential returns per unit of risk. The Dow Jones Industrial is currently generating roughly 0.08 per unit of risk.
NKGen Biotech, Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for NKGen Biotech,'s investment risk. Standard deviation is the most common way to measure market volatility of pink sheets, such as NKGen Biotech Common, and traders can use it to determine the average amount a NKGen Biotech,'s price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.2803
Best Portfolio
Best Equity
NKGN
Good Returns
Average Returns
Small Returns
Cash
Small Risk
Average Risk
High Risk
Huge Risk
Negative Returns
Based on monthly moving average NKGen Biotech, is performing at about 22% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of NKGen Biotech, by adding it to a well-diversified portfolio.
NKGen Biotech, Fundamentals Growth
NKGen Pink Sheet prices reflect investors' perceptions of the future prospects and financial health of NKGen Biotech,, and NKGen Biotech, fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on NKGen Pink Sheet performance.
By examining NKGen Biotech,'s fundamental ratios, stakeholders can obtain critical insights into NKGen Biotech,'s financial health, operational efficiency, and overall profitability. These insights assist in making well-informed investment and management decisions. For example, a high Return on Assets and Return on Equity would indicate that NKGen Biotech, is effectively utilizing its assets and equity to generate significant profits, enhancing its appeal to investors. On the other hand, low ROA and ROE values could reveal issues in asset and equity management, highlighting the need for operational improvements.
Things to note about NKGen Biotech Common performance evaluation
Checking the ongoing alerts about NKGen Biotech, for important developments is a great way to find new opportunities for your next move. Pink Sheet alerts and notifications screener for NKGen Biotech Common help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.
NKGen Biotech Common is way too risky over 90 days horizon
NKGen Biotech Common has some characteristics of a very speculative penny stock
NKGen Biotech Common appears to be risky and price may revert if volatility continues
NKGen Biotech Common has high likelihood to experience some financial distress in the next 2 years
Net Loss for the year was (82.95 M) with profit before overhead, payroll, taxes, and interest of 59 K.
NKGen Biotech, generates negative cash flow from operations
About 39.0% of the company outstanding shares are owned by corporate insiders
Evaluating NKGen Biotech,'s performance can involve analyzing a variety of financial metrics and factors. Some of the key considerations to evaluate NKGen Biotech,'s pink sheet performance include:
Analyzing NKGen Biotech,'s financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether NKGen Biotech,'s stock is overvalued or undervalued compared to its peers.
Examining NKGen Biotech,'s industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
Evaluating NKGen Biotech,'s management team can have a significant impact on its success or failure. Reviewing the track record and experience of NKGen Biotech,'s management team can help you assess the Company's leadership.
Pay attention to analyst opinions and ratings of NKGen Biotech,'s pink sheet. These opinions can provide insight into NKGen Biotech,'s potential for growth and whether the stock is currently undervalued or overvalued.
It's essential to remember that evaluating NKGen Biotech,'s pink sheet performance is not an exact science, and many factors can impact NKGen Biotech,'s pink sheet market price. Therefore, it's also important to diversify your portfolio and not rely solely on one company or stock for your investments.
Other Information on Investing in NKGen Pink Sheet
NKGen Biotech, financial ratios help investors to determine whether NKGen Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in NKGen with respect to the benefits of owning NKGen Biotech, security.